Tafasitamab and lenalidomide for returning CNS lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma that affects the brain, spinal cord, or eye fluid, and it has returned after previous treatment.
- You must be 18 years or older.
- You must be well enough to be up and about (performance status ECOG 0 or 1).
- Your kidney function must be adequate (creatinine clearance at least 60 mL/min).
- You must not have had prior treatment with anti-CD19 CAR-T therapy.
- If you have had a stem cell transplant, you must not have graft-versus-host disease and must be off immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for people with large B-cell lymphoma that has spread to the brain or spinal cord and has come back or not responded well to earlier treatments. The first drug, Relma-cel, is a type of immunotherapy that helps your immune system attack cancer cells. The second drug, Tislelizumab, helps keep your immune system active against the cancer.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests whether taking the drug tirabrutinib (a pill) can help keep primary CNS lymphoma from coming back after successful initial chemotherapy. It compares the drug to a placebo (a dummy pill).
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
Hear when a new CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.